{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:05:29Z","timestamp":1791155129931,"version":"4.1.0"},"reference-count":288,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.pharmthera.2012.04.002","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T07:38:58Z","timestamp":1334648338000},"page":"94-111","source":"Crossref","is-referenced-by-count":71,"title":["Impact of kinins in the treatment of cardiovascular diseases"],"prefix":"10.1016","volume":"135","author":[{"given":"Domenico","family":"Regoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard E.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"jr.","given":"Fernand","family":"Gobeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.04.002_bb0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","article-title":"Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization","volume":"48","author":"Abadir","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0010","doi-asserted-by":"crossref","first-page":"26079","DOI":"10.1074\/jbc.274.37.26079","article-title":"Involvement of the amino terminus of the B(2) receptor in agonist-induced receptor dimerization","volume":"274","author":"AbdAlla","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1385\/JMN:26:2-3:185","article-title":"Mesangial AT1\/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension","volume":"26","author":"AbdAlla","year":"2005","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0020","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5551\/jat.13.231","article-title":"AT1 receptor blockade prevents microvascular dysfunction induced by ischemia\/reperfusion injury","volume":"13","author":"Akiyoshi","year":"2006","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0030","first-page":"448","article-title":"Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis","volume":"17","author":"Al-Mallah","year":"2010","journal-title":"Cardiol J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0035","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2174\/138161211797416002","article-title":"Kinins as therapeutic agents in cardiovascular and renal diseases","volume":"17","author":"Alhenc-Gelas","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0040","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1139\/y95-240","article-title":"Kinin B1 and B2 receptors in the mouse","volume":"73","author":"Allogho","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0045","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1021\/jm9901529","article-title":"Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety","volume":"42","author":"Amblard","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0050","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0701813","article-title":"Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997","volume":"124","author":"Asano","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0060","doi-asserted-by":"crossref","first-page":"R2260","DOI":"10.1152\/ajpregu.00509.2007","article-title":"Acute angiotensin-converting enzyme inhibition evokes bradykinin-induced sympathetic activation in diabetic rats","volume":"293","author":"Augustyniak","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0065","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0070","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/clpt.2009.231","article-title":"Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials","volume":"87","author":"Baker-Smith","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/bj20021708","article-title":"Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells","volume":"371","author":"Barki-Harrington","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1051\/medsci\/200319111093","article-title":"Bradykinin receptors: towards new pathophysiological roles","volume":"19","author":"Bascands","year":"2003","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coph.2006.09.007","article-title":"Effects of anti-hypertensive drugs on vessel rarefaction","volume":"7","author":"Battegay","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.peptides.2008.12.003","article-title":"Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor","volume":"30","author":"B\u00e9langer","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0095","doi-asserted-by":"crossref","first-page":"H666","DOI":"10.1152\/ajpheart.00372.2006","article-title":"Angiotensin-(1\u20137) prevents diabetes-induced cardiovascular dysfunction","volume":"292","author":"Benter","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FJC.0b013e31821324b6","article-title":"Angiotensin-(1\u20137) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester","volume":"57","author":"Benter","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0105","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/sj.bjp.0701246","article-title":"Signalling pathways in bradykinin- and nitric oxide-induced hypotension in the normotensive rat; role of K+-channels","volume":"121","author":"Berg","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0110","first-page":"1","article-title":"Bioregulation of kinins: kallikreins, kininogens, and kininases","volume":"44","author":"Bhoola","year":"1992","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1189\/jlb.68.5.587","article-title":"Kinins and kinin receptors: importance for the activation of leukocytes","volume":"68","author":"Bockmann","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1096\/fj.08-106591","article-title":"Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone","volume":"23","author":"Bolego","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0361-9230(03)00043-1","article-title":"Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport","volume":"60","author":"Borlongan","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","article-title":"Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors","volume":"121","author":"Bosnyak","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.21933","article-title":"Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli","volume":"222","author":"Bovenzi","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0140","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.HYP.27.3.523","article-title":"Angiotensin-(1\u20137) dilates canine coronary arteries through kinins and nitric oxide","volume":"27","author":"Brosnihan","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0150","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0155","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/01.CIR.94.7.1752","article-title":"Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion","volume":"94","author":"Brunner","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0196-9781(93)90098-2","article-title":"Structure-activity studies of bradykinin analogues on rat mast cell histamine release","volume":"14","author":"Bueb","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0165","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1440-1681.2001.03564.x","article-title":"The kallikrein-kinin system in humans","volume":"28","author":"Campbell","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/01.HYP.23.4.439","article-title":"Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides","volume":"23","author":"Campbell","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0180","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1440-1681.2011.05572.x","article-title":"Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart","volume":"38","author":"Campbell","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0185","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00004872-200308000-00025","article-title":"Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program","volume":"21","author":"Campbell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0190","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00424-010-0804-6","article-title":"Epoxyeicosatrienoic acids and endothelium-dependent responses","volume":"459","author":"Campbell","year":"2010","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2202-5-38","article-title":"Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model","volume":"5","author":"Cardoso","year":"2004","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2008.01.003","article-title":"Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure","volume":"19","author":"Carey","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0205","doi-asserted-by":"crossref","first-page":"I4","DOI":"10.1161\/01.HYP.3.3_Pt_2.I4","article-title":"Possible role of kinins in circulatory homeostasis. State of the art review","volume":"3","author":"Carretero","year":"1981","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0210","series-title":"Conference","first-page":"63","article-title":"Kinin paracrine hormone","author":"Carretero","year":"1989"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1113\/expphysiol.2004.028464","article-title":"Kallikrein-kinin in stroke, cardiovascular and renal disease","volume":"90","author":"Chao","year":"2005","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1515\/bc.2010.042","article-title":"Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing","volume":"391","author":"Chao","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0225","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.0000255925.01707.eb","article-title":"Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity","volume":"49","author":"Chao","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0230","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1590\/S0100-879X1998000900014","article-title":"Antihypertensive effects of angiotensin-(1\u20137)","volume":"31","author":"Chappell","year":"1998","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0235","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1096\/fj.06-6113com","article-title":"Human ACE and bradykinin B2 receptors form a complex at the plasma membrane","volume":"20","author":"Chen","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(98)01346-4","article-title":"Pathogenesis, prevention, and treatment of diabetic nephropathy","volume":"352","author":"Cooper","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0245","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s001250100000","article-title":"Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy","volume":"44","author":"Cooper","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0250","series-title":"ACE inhibitors","first-page":"177","article-title":"ACE and Diabetes","author":"Cooper","year":"2001"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0255","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.peptides.2008.12.018","article-title":"Novel kinin B1 receptor agonists with improved pharmacological profiles","volume":"30","author":"C\u00f4t\u00e9","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejphar.2004.07.045","article-title":"Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus","volume":"500","author":"Couture","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(01)01318-8","article-title":"Kinin receptors in pain and inflammation","volume":"429","author":"Couture","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0270","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1517\/14656566.2010.521742","article-title":"Which antihypertensive drugs are the most nephroprotective and why?","volume":"11","author":"Cravedi","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2005.05.038","article-title":"Clots, kinins and coronaries","volume":"183","author":"Cruden","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00380-011-0124-6","article-title":"Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb","volume":"27","author":"Cruden","year":"2011","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199732010-00001","article-title":"Pharmacokinetic\u2013pharmacodynamic profile of angiotensin II receptor antagonists","volume":"32","author":"Csajka","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2011.556617","article-title":"Combined neutral endopeptidase inhibitors","volume":"20","author":"Cuculi","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0295","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1476-5381.1989.tb11903.x","article-title":"Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells","volume":"96","author":"D'Orleans-Juste","year":"1989","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0300","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ajh\/5.2.95","article-title":"Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies","volume":"5","author":"Dahlof","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0310","first-page":"415","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0315","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0162-3109(99)00078-8","article-title":"Structural requirements for B2-agonists with improved degradation stability","volume":"45","author":"Dendorfer","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.38.1.142","article-title":"Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation","volume":"38","author":"Dendorfer","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.HYP.35.1.32","article-title":"Potentiation of the vascular response to kinins by inhibition of myocardial kininases","volume":"35","author":"Dendorfer","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0330","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.amjcard.2011.06.046","article-title":"Effect of Joint National Committee VII Report on Hospitalizations for Hypertensive Emergencies in the United States","volume":"108","author":"Deshmukh","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.110.231308","article-title":"Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology","volume":"109","author":"DeWire","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0340","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0345","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF01720357","article-title":"New aspects of the blood flow-augmenting and insulin-like activity of muscle exercise: possible involvement of the kallikrein-kinin-prostaglandin system (author's transl)","volume":"60","author":"Dietze","year":"1982","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0350","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(88)90423-2","article-title":"[Phe8 psi(CH2-NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase II","volume":"155","author":"Drapeau","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0166-2236(93)90133-7","article-title":"Bradykinin and inflammatory pain","volume":"16","author":"Dray","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0360","doi-asserted-by":"crossref","first-page":"40375","DOI":"10.1074\/jbc.M202744200","article-title":"A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation","volume":"277","author":"Duchene","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0365","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.bbrc.2004.11.126","article-title":"Direct protein-protein interaction between PLCgamma1 and the bradykinin B2 receptor\u2013importance of growth conditions","volume":"326","author":"Duchene","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0370","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00382.2005","article-title":"Role of bradykinin B1 and B2 receptors in normal blood pressure regulation","volume":"291","author":"Duka","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0375","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/HYPERTENSIONAHA.107.108506","article-title":"Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors","volume":"51","author":"Duka","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0380","doi-asserted-by":"crossref","first-page":"50D","DOI":"10.1016\/0002-9149(87)90053-1","article-title":"Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme","volume":"59","author":"Dusing","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0385","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198006193022501","article-title":"Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure","volume":"302","author":"Dzau","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0390","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200140020-00003","article-title":"The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood\u2013brain barrier: from concept to clinical evaluation","volume":"40","author":"Emerich","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0395","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.HYP.16.4.363","article-title":"Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture","volume":"16","author":"Erdos","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0400","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/BC.2001.007","article-title":"Kinins, receptors, kininases and inhibitors\u2013where did they lead us?","volume":"382","author":"Erdos","year":"2001","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0405","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1043-2760(99)00156-3","article-title":"Potentiation of bradykinin actions by ACE inhibitors","volume":"10","author":"Erdos","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0410","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/HYPERTENSIONAHA.109.144600","article-title":"Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function","volume":"55","author":"Erdos","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0415","series-title":"The Kinin system","first-page":"249","article-title":"The kallikrein-kinin System in Asthma an Acute Respiratory Distress Syndrome","author":"Farmer","year":"1997"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0420","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20090096","article-title":"EDHF: an update","volume":"117","author":"Feletou","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0425","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1139\/y97-072","article-title":"Transient ischemia inhibits nonexocytotic release of norepinephrine following sustained ischemia in rat heart: is bradykinin involved?","volume":"75","author":"Feng","year":"1997","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0430","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10557-010-6244-x","article-title":"Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium","volume":"24","author":"Ferrari","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0435","doi-asserted-by":"crossref","first-page":"H2281","DOI":"10.1152\/ajpheart.00618.2005","article-title":"Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1\u20137) in regulation of cardiovascular function","volume":"289","author":"Ferrario","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0440","doi-asserted-by":"crossref","first-page":"H1113","DOI":"10.1152\/ajpheart.00828.2006","article-title":"The nonpeptide angiotensin-(1\u20137) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction","volume":"292","author":"Ferreira","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0445","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1476-5381.1967.tb02148.x","article-title":"The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat","volume":"30","author":"Ferreira","year":"1967","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0450","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/bi00815a005","article-title":"Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom","volume":"9","author":"Ferreira","year":"1970","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0455","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","article-title":"Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans","volume":"117","author":"Fisher","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0460","doi-asserted-by":"crossref","first-page":"H277","DOI":"10.1152\/ajpheart.01124.2002","article-title":"Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor?","volume":"285","author":"Fortin","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0465","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1476-5381.1994.tb17085.x","article-title":"Role of K+ channels in the vasodilator response to bradykinin in the rat heart","volume":"113","author":"Fulton","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0470","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1021\/bi00282a035","article-title":"Human kidney \u201cenkephalinase\u201d, a neutral metalloendopeptidase that cleaves active peptides","volume":"22","author":"Gafford","year":"1983","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0475","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJM198812083192310","article-title":"The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases","volume":"319","author":"Gavras","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0480","series-title":"ACE inhibitors","first-page":"77","article-title":"The role of ACE inhibition in heart failure","author":"Gavras","year":"2001"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0485","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult \u2013 2009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0490","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0166-2236(93)90191-N","article-title":"Receptor-independent activation of mast cells by bradykinin and related peptides","volume":"16","author":"Gies","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0495","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00005344-198405000-00010","article-title":"Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects","volume":"6","author":"Given","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0500","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0162-3109(99)00129-0","article-title":"Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657)","volume":"43","author":"Gobeil","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0505","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1139\/y02-014","article-title":"Studies on the angiotensin-converting enzyme and the kinin B2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin","volume":"80","author":"Gobeil","year":"2002","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0510","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1476-5381.1996.tb15401.x","article-title":"Receptors for kinins in the human isolated umbilical vein","volume":"118","author":"Gobeil","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0515","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/str.33.3.661","article-title":"Endothelium-derived hyperpolarizing factor in the brain: a new regulator of cerebral blood flow?","volume":"33","author":"Golding","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0520","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1381612054367418","article-title":"Antihypertensive therapy: role of aldosterone antagonists","volume":"11","author":"Grandi","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0525","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1096\/fj.04-3508fje","article-title":"Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia","volume":"19","author":"Griol-Charhbili","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0530","doi-asserted-by":"crossref","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","article-title":"Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1\u20137)","volume":"292","author":"Grobe","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0535","first-page":"3","article-title":"Prostacyclin among prostanoids","volume":"60","author":"Gryglewski","year":"2008","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0540","first-page":"397","article-title":"Secretory function of vascular endothelium","volume":"17A","author":"Gryglewski","year":"1987","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0545","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0828-282X(10)70379-2","article-title":"The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy","volume":"26","author":"Hackam","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0550","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0163-7258(92)90016-S","article-title":"Bradykinin receptors: pharmacological properties and biological roles","volume":"56","author":"Hall","year":"1992","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-3623(96)00174-7","article-title":"Bradykinin receptors","volume":"28","author":"Hall","year":"1997","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0560","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1074\/jbc.M804607200","article-title":"Lack of evidence for AT1R\/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R\/B2R heterodimer?","volume":"284","author":"Hansen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0565","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0570","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0575","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/hr.2010.147","article-title":"The counterregulating role of ACE2 and ACE2-mediated angiotensin 1\u20137 signaling against angiotensin II stimulation in vascular cells","volume":"33","author":"Hayashi","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0580","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/13543784.12.5.759","article-title":"The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease","volume":"12","author":"Heitsch","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0585","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0006-291X(92)91187-U","article-title":"Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor","volume":"184","author":"Hess","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0590","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCRESAHA.111.240986","article-title":"Arteriogenesis is modulated by bradykinin receptor signaling","volume":"109","author":"Hillmeister","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0595","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0600","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/01.HYP.0000064942.77814.26","article-title":"AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin\/B2-receptor-dependent mechanism","volume":"41","author":"Hornig","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0605","doi-asserted-by":"crossref","first-page":"16847","DOI":"10.1074\/jbc.M200355200","article-title":"Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor","volume":"277","author":"Ignjatovic","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0610","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1124\/mol.104.001990","article-title":"Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands","volume":"66","author":"Ignjatovic","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0615","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1081\/CEH-200044262","article-title":"Interleukin-1beta enhanced action of kinins on extracellular matrix of spontaneous hypertensive rat cardiac fibroblasts","volume":"27","author":"Imai","year":"2005","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0620","series-title":"Top Therapeutic Classes by U.S. Dispensed Prescriptions","author":"IMS_Health","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0625","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.HYP.0000097548.92665.16","article-title":"Role of endothelium-derived hyperpolarizing factor in human forearm circulation","volume":"42","author":"Inokuchi","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0630","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","article-title":"Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1\u20137)-Mas receptor axis","volume":"32","author":"Iwai","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0635","doi-asserted-by":"crossref","first-page":"H2356","DOI":"10.1152\/ajpheart.00317.2005","article-title":"Angiotensin-(1\u20137) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects","volume":"289","author":"Iwata","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0640","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","first-page":"789","article-title":"Renin and Angiotensin","author":"Jackson","year":"2006"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0645","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","article-title":"Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs","volume":"32","author":"Jalowy","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0650","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mi.10.2.2","article-title":"Private development companies: transforming academic research into new treatment options for cancer","volume":"10","author":"Janoff","year":"2010","journal-title":"Mol Interv"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0655","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/j.1365-2982.2010.01646.x","article-title":"Nitric oxide in enteric nervous system mediated the inhibitory effect of vasopressin on the contraction of circular muscle strips from colon in male rats","volume":"23","author":"Jing","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0660","series-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","first-page":"86","author":"JNC7","year":"2004"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0665","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2008.08.009","article-title":"AT2 receptors: functional relevance in cardiovascular disease","volume":"120","author":"Jones","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0670","doi-asserted-by":"crossref","first-page":"24025","DOI":"10.1074\/jbc.273.37.24025","article-title":"Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase","volume":"273","author":"Ju","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0675","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2008.647","article-title":"The kallikrein-kinin system in health and in diseases of the kidney","volume":"75","author":"Kakoki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0680","doi-asserted-by":"crossref","first-page":"13302","DOI":"10.1073\/pnas.0405449101","article-title":"Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor","volume":"101","author":"Kakoki","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0685","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1073\/pnas.0701617104","article-title":"Bradykinin B1 and B2 receptors both have protective roles in renal ischemia\/reperfusion injury","volume":"104","author":"Kakoki","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0690","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI26958","article-title":"Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors","volume":"116","author":"Kakoki","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0695","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1073\/pnas.1005144107","article-title":"Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice","volume":"107","author":"Kakoki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0700","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0705","first-page":"33","article-title":"ACE inhibitor-induced angioedema: a case report and review of current management","volume":"13","author":"Kloth","year":"2011","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0710","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.npep.2009.12.004","article-title":"Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors","volume":"44","author":"Kuhr","year":"2010","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0715","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0720","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjp.0703880","article-title":"Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse","volume":"132","author":"Labonte","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0725","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S1567-5769(03)00177-2","article-title":"A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart","volume":"3","author":"Lagneux","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0730","series-title":"ACE inhibitors","first-page":"47","article-title":"Evaluative and epidemiological approaches of ACE therapy","author":"Lamarre-Cliche","year":"2001"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0735","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1113\/jphysiol.2002.018077","article-title":"Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans","volume":"542","author":"Langberg","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0740","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0745","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0735-1097(99)00297-1","article-title":"Bradykinin-induced preconditioning in patients undergoing coronary angioplasty","volume":"34","author":"Leesar","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0750","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0755","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.yjmcc.2007.08.007","article-title":"Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells","volume":"43","author":"Liesmaa","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0760","first-page":"25","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0765","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0008-6363(99)00091-7","article-title":"Interactions among ACE, kinins and NO","volume":"43","author":"Linz","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0770","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jcb.20709","article-title":"Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts","volume":"97","author":"Liu","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0775","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.HYP.27.1.7","article-title":"Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia\/reperfusion injury in rats","volume":"27","author":"Liu","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0780","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors","volume":"99","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0785","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.peptides.2011.06.010","article-title":"Role of vascular Kinin B(1) and B(2) receptors in endothelial nitric oxide metabolism","volume":"32","author":"Loiola","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0790","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/01.CIR.0000013847.07035.B9","article-title":"Angiotensin-(1\u20137) attenuates the development of heart failure after myocardial infarction in rats","volume":"105","author":"Loot","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0795","first-page":"R72","article-title":"The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin","volume":"262","author":"Lortie","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0800","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mce.2008.09.018","article-title":"Functional interactions between 7TM receptors in the renin-angiotensin system\u2013dimerization or crosstalk?","volume":"302","author":"Lyngso","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0805","article-title":"Stem cell therapy for cardiovascular regeneration: The beginning or the end of all hearts' hopes","author":"Madeddu","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0810","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ncpneph0444","article-title":"Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling","volume":"3","author":"Madeddu","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0815","series-title":"The Kinin system","first-page":"235","article-title":"Bradykinin as an Inflammatory Mediator in the Urinary Tract","author":"Maggi","year":"1997"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0820","first-page":"S45","article-title":"Reflex control of circulation and angiotensin converting enzyme inhibition in man","volume":"6","author":"Mancia","year":"1988","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0825","doi-asserted-by":"crossref","first-page":"c1197","DOI":"10.1136\/bmj.c1197","article-title":"Statins, antihypertensive treatment, and blood pressure control in clinic and over 24hours: evidence from PHYLLIS randomised double blind trial","volume":"340","author":"Mancia","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0830","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0835","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.CIR.94.3.258","article-title":"Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study","volume":"94","author":"Mancini","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0840","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archinte.1995.00430080067009","article-title":"Trends in pharmacologic management of hypertension in the United States","volume":"155","author":"Manolio","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0845","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/hr.2010.82","article-title":"Cardioprotective properties of bradykinin: role of the B(2) receptor","volume":"33","author":"Manolis","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0162-3109(95)00011-H","article-title":"Kinin B1 receptors: a review","volume":"30","author":"Marceau","year":"1995","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0855","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd1522","article-title":"Bradykinin receptor ligands: therapeutic perspectives","volume":"3","author":"Marceau","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0860","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjp.2008.233","article-title":"Therapeutic options in inflammatory bowel disease: experimental evidence of a beneficial effect of kinin B1 receptor blockade","volume":"154","author":"Marceau","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0865","first-page":"357","article-title":"The B1 receptors for kinins","volume":"50","author":"Marceau","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0870","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1152\/ajplegacy.1972.223.4.794","article-title":"Evidence for an involvement of kinins in regulation of sodium excretion","volume":"223","author":"Marin-Grez","year":"1972","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0875","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ajh.2010.20","article-title":"Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct","volume":"23","author":"Marketou","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0880","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","article-title":"An oral formulation of angiotensin-(1\u20137) produces cardioprotective effects in infarcted and isoproterenol-treated rats","volume":"57","author":"Marques","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0885","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.297.6656.1092","article-title":"Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria","volume":"297","author":"Marre","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0890","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1253\/jcj.65.1052","article-title":"Coronary vasomotor responses to bradykinin and acetylcholine in patients with coronary spastic angina","volume":"65","author":"Matsumoto","year":"2001","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0895","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/jc.86.2.713","article-title":"Insulin resistance and cardiovascular disease","volume":"86","author":"McFarlane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0900","doi-asserted-by":"crossref","first-page":"30H","DOI":"10.1016\/S0002-9149(03)00432-6","article-title":"Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease","volume":"91","author":"McFarlane","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0905","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjp.0702743","article-title":"Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation","volume":"128","author":"McLean","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0910","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/physrev.00012.2005","article-title":"Signaling mechanisms regulating endothelial permeability","volume":"86","author":"Mehta","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0915","doi-asserted-by":"crossref","first-page":"21583","DOI":"10.1016\/S0021-9258(17)31844-6","article-title":"Expression cloning of a human B1 bradykinin receptor","volume":"269","author":"Menke","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0920","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00109-008-0345-z","article-title":"Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors","volume":"86","author":"Merino","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0925","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2008.04902.x","article-title":"Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice","volume":"35","author":"Messadi-Laribi","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0930","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0735-1097(01)01202-5","article-title":"Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors","volume":"37","author":"Minai","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0935","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/jmcc.1998.0844","article-title":"Endothelial dysfunction: from physiology to therapy","volume":"31","author":"Mombouli","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0940","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.HYP.21.6.921","article-title":"Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin","volume":"21","author":"Momose","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0945","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.4049\/jimmunol.177.9.6325","article-title":"Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi","volume":"177","author":"Monteiro","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0950","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.peptides.2007.12.004","article-title":"Lack of direct interaction between enalaprilat and the kinin B1 receptors","volume":"29","author":"Morissette","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0955","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0165-6147(90)90179-C","article-title":"G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides","volume":"11","author":"Mousli","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0960","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/jpet.106.104026","article-title":"Bradykinin and its metabolite bradykinin 1\u20135 inhibit thrombin-induced platelet aggregation in humans","volume":"318","author":"Murphey","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/ajrcmb\/8.1.1","article-title":"Endothelium-derived hyperpolarizing factor and endothelium-dependent relaxations","volume":"8","author":"Nagao","year":"1993","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0970","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1172\/JCI116907","article-title":"Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries","volume":"92","author":"Nakashima","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0975","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/216762a0","article-title":"Conversion of angiotensin I to angiotensin II","volume":"216","author":"Ng","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0980","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/PL00005157","article-title":"Effects of kinins on isolated stomachs of control and transgenic knockout B2 receptor mice","volume":"357","author":"Nsa Allogho","year":"1998","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0985","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10409238409108720","article-title":"Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions","volume":"16","author":"Ondetti","year":"1984","journal-title":"CRC Crit Rev Biochem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0990","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1021\/bi00798a004","article-title":"Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis","volume":"10","author":"Ondetti","year":"1971","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb0995","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-6147(94)90129-5","article-title":"Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation","volume":"15","author":"Parratt","year":"1994","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1000","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1139\/y95-114","article-title":"Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning\u2013a brief review of the evidence","volume":"73","author":"Parratt","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1515\/BC.2006.017","article-title":"Genetically altered animal models in the kallikrein-kinin system","volume":"387","author":"Pesquero","year":"2006","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.med.46.1.455","article-title":"Left ventricular remodeling after acute myocardial infarction","volume":"46","author":"Pfeffer","year":"1995","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.0000141438.64887.42","article-title":"Nonpeptide AVE 0991 is an angiotensin-(1\u20137) receptor Mas agonist in the mouse kidney","volume":"44","author":"Pinheiro","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1025","first-page":"445","article-title":"Cytochrome P-450-dependent monooxygenase activity and endothelial-dependent relaxations induced by arachidonic acid","volume":"236","author":"Pinto","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1030","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0735-1097(98)00611-1","article-title":"Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin","volume":"33","author":"Prasad","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/01.CIR.0000046268.59922.A4","article-title":"Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin","volume":"107","author":"Pretorius","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1040","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/archinte.162.20.2325","article-title":"Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study","volume":"162","author":"Psaty","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1045","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.2174\/138161205774424708","article-title":"Vasopeptidase inhibition for blood pressure control: emerging experience","volume":"11","author":"Quaschning","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000097625","article-title":"Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension","volume":"29","author":"Quaschning","year":"2006","journal-title":"Kidney Blood Press Res"},{"issue":"415\u2013433","key":"10.1016\/j.pharmthera.2012.04.002_bb1055","first-page":"e412","article-title":"The 2011 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy","volume":"27","author":"Rabi","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1060","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/j.1476-5381.1996.tb15566.x","article-title":"Contribution of calcium-activated potassium channels to the vasodilator effect of bradykinin in the isolated, perfused kidney of the rat","volume":"118","author":"Rapacon","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1070","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1075","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2174\/1381612043384709","article-title":"Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies","volume":"10","author":"Regoli","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1080","first-page":"1","article-title":"Pharmacology of bradykinin and related kinins","volume":"32","author":"Regoli","year":"1980","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1085","first-page":"64","article-title":"Peptide receptors. From classical pharmacology to molecular biology: The case of kinin receptors","volume":"vol. 307","author":"Regoli","year":"1999"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1090","first-page":"69","article-title":"Pharmacology of angiotensin","volume":"26","author":"Regoli","year":"1974","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(81)90391-5","article-title":"Induction of B1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide","volume":"71","author":"Regoli","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0165-6147(90)90067-I","article-title":"New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization","volume":"11","author":"Regoli","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00165-4","article-title":"Bradykinin receptors and their antagonists","volume":"348","author":"Regoli","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1110","series-title":"Conference","first-page":"97","article-title":"New aspects of local vasodilatory and metabolic effects of the kallikrein-kinin system. its role during muscle work","author":"Rett","year":"1989"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/cphy.c100053","article-title":"The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function","author":"Rhaleb","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/13543784.2010.514902","article-title":"Aliskiren: beyond blood pressure reduction","volume":"19","author":"Riccioni","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2174\/1381612053507422","article-title":"Targeting kinin receptors for the treatment of neurological diseases","volume":"11","author":"Rodi","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nephro.2007.03.003","article-title":"Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers","volume":"3","author":"Roskiewicz","year":"2007","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000138659","article-title":"Inhibitors of peptidases: how they influence the biological activities of substance P, neurokinins, bradykinin and angiotensin in guinea pig, hamster and rat urinary bladders","volume":"40","author":"Rouissi","year":"1990","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000138658","article-title":"Inhibitors of peptidases: how they influence the biological activities of substance P, neurokinins, kinins and angiotensins in isolated vessels","volume":"40","author":"Rouissi","year":"1990","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lfs.2010.10.017","article-title":"Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease","volume":"88","author":"Ruan","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bjp.0705236","article-title":"Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats","volume":"139","author":"Santos","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/13543784.14.8.1019","article-title":"Angiotensin-(1\u20137) and its receptor as a potential targets for new cardiovascular drugs","volume":"14","author":"Santos","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/FJC.0b013e31818127f8","article-title":"Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts","volume":"52","author":"Sasaoka","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1165","doi-asserted-by":"crossref","first-page":"III346","DOI":"10.1161\/01.CIR.102.suppl_3.III-346","article-title":"Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms","volume":"102","author":"Sato","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1172\/JCI0215493","article-title":"In vivo bradykinin B2 receptor activation reduces renal fibrosis","volume":"110","author":"Schanstra","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1175","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1084\/jem.192.9.1289","article-title":"Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors","volume":"192","author":"Scharfstein","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1180","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.1980","article-title":"Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system","volume":"15","author":"Schulze-Topphoff","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1185","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.RES.81.5.774","article-title":"Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine\/paracrine mechanisms","volume":"81","author":"Seyedi","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1190","doi-asserted-by":"crossref","first-page":"17962","DOI":"10.1074\/jbc.M106101200","article-title":"Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator","volume":"277","author":"Shariat-Madar","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1195","doi-asserted-by":"crossref","first-page":"H2697","DOI":"10.1152\/ajpheart.00715.2005","article-title":"Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells","volume":"289","author":"Shariat-Madar","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1100\/tsw.2008.53","article-title":"Cardiovascular activities of the bradykinin system","volume":"8","author":"Sharma","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1205","first-page":"926","article-title":"Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases","volume":"7","author":"Sharma","year":"2004","journal-title":"IDrugs"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1210","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjoto.2010.11.014","article-title":"Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis","volume":"32","author":"Shino","year":"2011","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1220","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.103.3.295","article-title":"The preparation and function of the hypertensin-converting enzyme","volume":"103","author":"Skeggs","year":"1956","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1230","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V66.4.835.835","article-title":"Tissue plasminogen activator release in vivo in response to vasoactive agents","volume":"66","author":"Smith","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1235","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ibd.21337","article-title":"Intestinal tissue kallikrein-kinin system in inflammatory bowel disease","volume":"17","author":"Stadnicki","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1245","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/jpet.105.093849","article-title":"Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells","volume":"316","author":"Stanisavljevic","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1470320309347791","article-title":"The past, present and future of angiotensin II type 2 receptor stimulation","volume":"11","author":"Steckelings","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1255","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2174\/138161206778194051","article-title":"Kinins and cardiovascular diseases","volume":"12","author":"Su","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1260","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1161\/01.CIR.101.15.1848","article-title":"Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation","volume":"101","author":"Su","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1265","doi-asserted-by":"crossref","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","article-title":"Angiotensin-(1\u20137) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1270","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.peptides.2005.03.050","article-title":"Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy","volume":"26","author":"Taraseviciene-Stewart","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1275","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","author":"The_ACE_Inhibitors_in_Diabetic_Nephropathy_Trialist_Group","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1280","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","author":"The_GISEN_Group","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1285","doi-asserted-by":"crossref","first-page":"H1425","DOI":"10.1152\/ajpheart.00783.2003","article-title":"ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles","volume":"286","author":"Tiefenbacher","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1290","first-page":"205","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1295","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.bjp.0704862","article-title":"Bradykinin potentiation by ACE inhibitors: a matter of metabolism","volume":"137","author":"Tom","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/01.CIR.0000105726.89770.35","article-title":"Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs","volume":"109","author":"Tonduangu","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1305","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cardiores.2003.10.018","article-title":"The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction","volume":"61","author":"Tschope","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1310","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI7886","article-title":"Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation","volume":"104","author":"Tsutsumi","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1470320309347792","article-title":"Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential","volume":"11","author":"Unger","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1320","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1476-5381.1969.tb07982.x","article-title":"The release and fate of vaso-active hormones in the circulation","volume":"35","author":"Vane","year":"1969","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1098\/rstb.1994.0023","article-title":"The Croonian Lecture, 1993: The Endothelium: Maestro of the Blood Circulation","volume":"343","author":"Vane","year":"1994","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1330","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1253\/circj.CJ-08-1169","article-title":"Endothelial dysfunction: the first step toward coronary arteriosclerosis","volume":"73","author":"Vanhoutte","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1335","doi-asserted-by":"crossref","first-page":"3E","DOI":"10.1016\/0002-9149(95)90044-6","article-title":"Endothelium-derived relaxing factors and converting enzyme inhibition","volume":"76","author":"Vanhoutte","year":"1995","journal-title":"Am J Cardiol"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2012.04.002_bb1340","first-page":"565","article-title":"Pseudopeptide analogs of bradykinin and bradykinin antagonists","volume":"38","author":"Vavrek","year":"1992","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1345","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0002-8703(82)90278-2","article-title":"Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity","volume":"103","author":"Waeber","year":"1982","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1350","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","article-title":"Angiotensin-(1\u20137) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats","volume":"45","author":"Walters","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/14017430802180449","article-title":"The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning)","volume":"43","author":"Wang","year":"2009","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1360","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.athoracsur.2003.11.039","article-title":"Bradykinin preconditioning in coronary artery bypass grafting","volume":"78","author":"Wei","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1365","first-page":"323","article-title":"Differential distribution of angiotensin AT2 receptors in the normal and failing human heart","volume":"284","author":"Wharton","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1370","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.HYP.0000037979.53963.8F","article-title":"AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1\u20137) on the endothelium","volume":"40","author":"Wiemer","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1375","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM198812083192305","article-title":"Converting-enzyme inhibitors in the treatment of hypertension","volume":"319","author":"Williams","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1380","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0008-6363(99)00145-5","article-title":"The renin-angiotensin system and experimental heart failure","volume":"43","author":"Wollert","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1385","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1161\/CIRCULATIONAHA.107.752865","article-title":"Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice","volume":"118","author":"Xi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1390","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.HYP.0000029095.23198.AD","article-title":"Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice","volume":"40","author":"Xu","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1395","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1113\/expphysiol.2008.045583","article-title":"The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice","volume":"94","author":"Xu","year":"2009","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1400","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.HYP.19.6.799","article-title":"Effect of intrarenal bradykinin infusion on vasopressin release in rabbits","volume":"19","author":"Yamamoto","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1405","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.cardfail.2007.04.009","article-title":"Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction","volume":"13","author":"Yao","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1410","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1415","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1420","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1074\/jbc.M709837200","article-title":"Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists","volume":"283","author":"Zhang","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1425","doi-asserted-by":"crossref","first-page":"18547","DOI":"10.1074\/jbc.M110.214940","article-title":"Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling","volume":"286","author":"Zhang","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1430","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/FJC.0b013e3181e5f2e2","article-title":"Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors","volume":"56","author":"Zhang","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1435","doi-asserted-by":"crossref","first-page":"H1821","DOI":"10.1152\/ajpheart.2001.280.4.H1821","article-title":"Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation","volume":"280","author":"Zhao","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1440","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/HYPERTENSIONAHA.110.155051","article-title":"Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells","volume":"56","author":"Zhu","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.002_bb1445","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00005344-199905000-00016","article-title":"Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts","volume":"33","author":"Zhu","year":"1999","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T01:31:55Z","timestamp":1687397515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":288,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0163725812000794"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.04.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}